1816370207
Medical Device Global Market Access

Advertise on podcast: Medical Device Global Market Access

Rating
★★★★★
5
from
1 reviews
Categories
This podcast has
495 episodes
Language
English
Publisher
Pure Global
Explicit
No
Date created
2025/05/24
Latest episode
2026/11/16
Average duration
6 min.
Release period
1 days

Description

Navigate every market. Accelerate every launch. Medical Device Global Market Access by Pure Global is the audio briefing that turns the world’s most confusing regulatory pathways into clear, actionable roadmaps. If you’re a MedTech founder, RA/QA leader, product manager, or investor who needs to get devices cleared anywhere from Austin to Abu Dhabi, this show is your shortcut. Why listen? • Step-by-step playbooks – We decode EU MDR, U.S. 510(k), Brazil’s ANVISA, China’s NMPA, and 25 + other regimes, showing exactly how long each milestone really takes and where companies get stuck. • First-hand war stories – Hear candid interviews with regulatory veterans who have shepherded implants, software, wearables, diagnostics, and AI algorithms to market—and lived to tell the tale. • Real-time intelligence – Every episode covering the week’s new guidances, standards, and enforcement trends so you’re always ahead of the curve. • Actionable templates – From clinical evaluation checklists to technical-file skeletons, we break down the documents you’ll need and the pitfalls reviewers love to flag. • AI-powered insights – Because Pure Global mines millions of public filings, tenders, and recalls, we surface data-backed best practices you won’t hear at conferences—or from competitors. What you’ll hear • Launching SaMD under multiple risk classes in parallel • Surviving an unannounced ISO 13485 audit • Building a “reg-first” QMS that scales • Mastering Latin-American registrations without endless language cycles • Leveraging real-world evidence to shorten clinical timelines • Aligning cybersecurity, privacy, and post-market surveillance rules across regions Whether you’re plotting first entry, managing lifecycle expansions, or rescuing a delayed submission, subscribing could shave months—and millions—off your path to revenue. ⸻ Brought to you by Pure Global – the AI-native consultancy that already guides MedTech innovators through regulatory and market-access hurdles in 30 + countries. Ready for expert help on your next submission? Visit https://pureglobal.com or email [email protected] to start accelerating today.

Unlock Medical Device Global Market Access podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Podcast episodes

Check latest episodes from Medical Device Global Market Access podcast


FDA IVD Emerging Pathogens Guidance: Validation for Section 564 Emergencies
2026/11/16
On November 9, 2026, the US FDA issued final guidance clarifying validation requirements for In Vitro Diagnostic (IVD) devices targeting emerging pathogens during a Section 564 declared emergency. This episode breaks down the key recommendations for manufacturers, including expectations for analytical and clinical validation, the use of contrived samples, and the impact on future Emergency Use Authorization (EUA) submissions. We outline practical steps that IVD companies can take now to align their internal processes with this guidance to ensure they are prepared for the next public health crisis. Key Questions: - What are the FDA's new validation expectations for IVD tests during a public health emergency? - How does the November 9, 2026 guidance affect the Emergency Use Authorization (EUA) process? - What specific recommendations does the FDA provide for using contrived samples when patient samples are scarce? - Which types of IVD manufacturers are most impacted by this new guidance? - What are the minimum requirements for analytical validation, such as limit of detection and specificity? - How does this guidance change the strategy for clinical validation studies for emerging pathogens? - What are four practical actions your regulatory team should take to prepare for these new requirements? - Why is early engagement with the FDA through pre-EUA submissions more critical now? Sources: - https://www.federalregister.gov/documents/2026/11/09/2026-22883/validation-of-certain-in-vitro-diagnostic-devices-for-emerging-pathogens-during-a-section-564 - https://www.fda.gov/news-events/cdrh-new-news-and-updates How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex requirements and accelerate market access. Our experts specialize in US FDA submissions, including Emergency Use Authorizations (EUAs) and pre-submission strategies. We can help you develop robust validation plans that align with the latest FDA guidance, prepare comprehensive technical dossiers, and manage communications with the agency to ensure a smooth review process. To learn how we can support your global market access goals, visit us at https://pureglobal.com or contact us at [email protected]. Explore our free AI-powered regulatory tools and device database at https://pureglobal.ai.
EU Harmonised Standards Update (November 2026): What MDR & IVDR Manufacturers Must Do Now
2026/11/15
On November 10, 2026, the European Commission published Implementing Decisions (EU) 2026/2479 and 2026/2481, updating the list of harmonised standards for the MDR and IVDR. This episode details the immediate legal effect of this publication, which grants a presumption of conformity when these standards are used. We discuss key changes, including updated standards for sterilization and clinical investigations, and outline the critical steps manufacturers must now take to review their declarations of conformity, update technical documentation, and ensure their products remain compliant on the EU market. Key Questions: - What are the legal implications of the new harmonised standards list published on November 10, 2026? - How do Implementing Decisions (EU) 2026/2479 and 2026/2481 affect my device's presumption of conformity? - Which key standards for sterilization and clinical investigation have been added or updated? - What happens if we are still using a standard that has now been superseded? - What is the first step our regulatory team should take to address these changes? - How should we update our technical documentation and Declaration of Conformity? - Do we need to inform our Notified Body about our transition plan? - What impact will these new standards have on our Quality Management System? Sources: - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF4RQ_qBL8mGuGEi-bU6lD5HHG7OsqeHQ1c1eRzd3ZkzR3r1ztcS9eXf5Od7pSrGsRtF6OYHHGhCWk-7YGPtJkoCEc4rvKwN2J8Xh-7eHkKdiP8iS0zbX8bgULIbzW-XbfV8_v3nUlAjdjCQD1cXJ02IKn5bgemr2U6CftDteyljABtEcFphjdjboXHGim3 - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEAuKcnT3D7fyWxiK3d7vF2jpt_OIp6pvIqwQb7bCTdFbUxZxw5eYKSlKgntx1hCHtViCG_tbvb2kzwxc5tV0MPkdCq6y1BdH1g-Znb3ABVgYQz6SR6x03GGjFQa8OtvxuzYxMX7LrTQ8eF_RxpQ_pON3Su-b1hnKtQW849_TPwGQh_aFzFS9j5CXn1-aIwcuOPRiZ3kdLakdE How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We can help you navigate the updated EU harmonised standards by developing an efficient regulatory strategy, performing gap analyses, and using advanced AI to compile and manage your technical dossiers for submission. Our local experts in over 30 markets ensure your products meet all requirements for initial registration and ongoing compliance. For support with your global expansion, contact us at [email protected] or visit https://pureglobal.com. Explore our free AI tools and global device database at https://pureglobal.ai.
China NMPA Medical Device GMP: Compliance for the November 1, 2026 Changes
2026/11/14
China's National Medical Products Administration (NMPA) has implemented its revised Good Manufacturing Practice (GMP) for Medical Devices and new 'Guidelines for Inspection of GMP,' effective November 1, 2026. This episode details the critical changes affecting all medical device manufacturers selling in China, replacing the 2014 version with a more stringent, risk-based framework. We cover the new 200-item inspection checklist, the addition of chapters on Quality Assurance and Contract Manufacturing, and the heightened focus on data integrity and supply chain oversight. Learn the immediate actions your quality and regulatory teams must take to ensure compliance and prepare for upcoming NMPA inspections under these new rules. Key Questions: - What are the major changes in China's new Medical Device GMP effective November 1, 2026? - How does the new 200-item inspection checklist impact NMPA audits? - What new requirements apply to contract manufacturing and quality assurance? - Which manufacturers are affected by these updated regulations? - How has the NMPA's approach to risk management evolved? - What are the immediate steps your quality team should take to ensure compliance? - Why is data integrity a critical focus in the new GMP guidelines? - What should foreign manufacturers do to prepare for inspections under the new rules? Sources: - https://www.cisema.com/en/cisema-news/china-nmpa-issues-new-medical-device-gmp-inspection-guidelines/ - https://www.dqs-med.com/en/news/chinas-new-medical-device-gmp-in-force-from-1-nov-2026 - https://www.emergobyul.com/news/china-nmpa-quality-management-system-qms-legislation-take-effect-november-1-2026 - https://www.chinameddevice.com/nmpa-roundup-october-2026/ - https://med.china-direct.net/new-medical-device-gmp-takes-effect-five-national-standards-also-implemented-from-november-1/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech companies navigating complex markets like China. Our local experts in China can help you perform a gap analysis of your QMS against the new NMPA GMP requirements, update your technical documentation, and prepare for rigorous on-site inspections. We act as your local representative and develop efficient regulatory strategies to ensure your products achieve and maintain compliance. Leverage our advanced AI tools to streamline dossier preparation and stay ahead of regulatory changes. Contact us at [email protected] or visit https://pureglobal.com to learn more. Explore our free AI tools and global database at https://pureglobal.ai.
Mexico COFEPRIS Extends Medical Device Registration Renewals to 10 Years
2026/11/13
This episode explores a significant regulatory update from Mexico's COFEPRIS concerning medical device registration renewals. Following a reform to Article 376 of the General Health Law, effective January 15, 2026, the validity of subsequent 'Registro Sanitario' renewals will be extended from five to ten years. We discuss how this change impacts manufacturers, what it means for long-term regulatory strategy, and the practical steps teams should take to prepare for this new, more efficient renewal cycle. Key Questions: - What specific change did Mexico's COFEPRIS make to medical device registration renewals? - When does the new ten-year renewal validity period take effect? - Does this change apply to the initial 'Registro Sanitario' or only to renewals? - How does this reform impact the long-term administrative burden for manufacturers? - What is the difference between the old five-year rule and the new ten-year rule? - Which device types and risk classes are affected by this policy change? - What should regulatory teams do now to prepare for the January 15, 2026 deadline? - How should companies adjust their regulatory budgets for the Mexican market? - Why is it important to communicate this change to your Mexico Registration Holder? Sources: - https://www.eilan-trade.com/importing-medical-devices-into-mexico-cofepris-and-customs/ - https://artixio.com/cofepris-medical-device-registration-in-mexico/ - https://www.emergobyul.com/news/mexicos-general-health-law-amended-renewal-registration-validity-extended - https://www.pure-global.com/post/mexico-extends-medical-device-registration-renewals-to-10-years-under-2026-general-health-law-reform - https://tetakawi.com/industries/medical-device/cofepris-registration-in-mexico/ How Pure Global can help: Pure Global streamlines global market access for MedTech and IVD companies. Our experts can help you navigate Mexico's COFEPRIS requirements, including the new 10-year renewal process. We act as your local representative, develop efficient regulatory strategies, and use advanced AI to compile and manage technical dossiers. With a single process, we can help you access over 30 markets, ensuring your products reach patients faster. For help with your market access strategy, visit us at https://pureglobal.com, email [email protected], or explore our free AI tools and regulatory database at https://pureglobal.ai.
EU MDCG 2026-4 Rev. 1: Manufacturers Now Responsible for EUDAMED SSCP Uploads
2026/11/12
The European Commission's Medical Device Coordination Group (MDCG) has updated its guidance with MDCG 2026-4 Rev. 1, shifting a key EUDAMED responsibility. This episode details the change, published on October 30, 2026, which transfers the obligation of uploading the Summary of Safety and Clinical Performance (SSCP) and Summary of Safety and Performance (SSP) from Notified Bodies directly to manufacturers. We discuss which devices are affected, the implementation timeline tied to EUDAMED's functionality deployment in December 2026, and the practical steps manufacturers must take now to update procedures and ensure a smooth transition. Key Questions: - What is the main change introduced in MDCG 2026-4 Rev. 1? - Who is now responsible for uploading the SSCP and SSP into the EUDAMED database? - Which classes of medical devices and IVDs are impacted by this new rule? - What is the effective date for manufacturers to take over this responsibility? - Why should manufacturers start preparing now, even if the EUDAMED module is not yet live? - What are the first steps to update a Quality Management System for this change? - How should manufacturers coordinate with their Notified Body during this transition? - What are the risks of not preparing for this shift in responsibility? Sources: - https://health.ec.europa.eu/latest-updates/new-revision-mdcg-position-paper-management-sscp-eudamed-after-mandatory-use-2026-10-30_en - https://www.easymedicaldevice.com/2026/11/05/medical-device-regulatory-update-november-2026/ - https://simoneronco.com/medical-device-news/26-october-1-november-2026-mdn-023/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We can help you navigate the complexities of EUDAMED compliance, including updating your QMS and technical dossiers to meet new requirements like those in MDCG 2026-4 Rev. 1. Our team of local experts, combined with advanced AI tools, ensures your submissions are efficient and accurate. From regulatory strategy and local representation to post-market surveillance, we manage the entire product lifecycle. Contact us at [email protected] or visit https://pureglobal.com to learn more. Explore our free AI tools and global device database at https://pureglobal.ai.
EU EUDAMED Device Registration Deadline: November 2026 Requirements for MDR and IVDR
2026/11/11
The European Union has set a mandatory deadline of November 28, 2026, for all medical devices and In-Vitro Diagnostics (IVDs) to be registered in the EUDAMED UDI/Device module. This requirement applies to all devices sold in the EU, including legacy devices under the MDD/IVDD and new devices compliant with the MDR/IVDR. Failure to meet this deadline will result in non-compliance, preventing manufacturers from legally placing their products on the EU market. This episode breaks down who is affected, the consequences of inaction, and provides practical, step-by-step guidance for regulatory and quality teams to ensure their device data is compiled, validated, and successfully submitted before this critical date. Key Questions: - What is the exact EUDAMED registration deadline for all medical devices? - Does this deadline apply to legacy devices under the MDD and IVDD? - What are the consequences of failing to register devices in EUDAMED by November 2026? - What specific data is required for the UDI/Device module registration? - How can manufacturers prepare their device data for a successful submission? - What is the difference between manual and machine-to-machine (M2M) EUDAMED submissions? - Why should manufacturers start the registration process now instead of waiting? - What are the first steps our team should take to prepare for this deadline? Sources: - https://www.obelis.net/eudamed-november-2026-deadline-device-registration-guide/ - https://health.ec.europa.eu/latest-updates/mdcg-2026-4-rev1-mdcg-position-paper-management-sscp-eudamed-after-mandatory-use-2026-10-30_en - https://www.ovasolutions.com/eu-mdr-deadlines/ - https://easymedicaldevice.com/medical-device-regulatory-update-november-2026/ How Pure Global can help: Pure Global offers end-to-end regulatory consulting to help MedTech and IVD companies navigate complex requirements like the EUDAMED registration deadline. Our experts develop efficient regulatory strategies and use advanced AI to compile, manage, and submit technical dossiers, ensuring compliance and speeding up market access. Whether you need help with data preparation, submission strategy, or acting as your local representative, we provide tailored solutions to keep your products on the market. Contact us at [email protected] or visit https://pureglobal.com to learn more. Explore our free AI tools and regulatory database at https://pureglobal.ai.
South Korea MFDS Proposes WHO Reliance for IVD Approvals
2026/11/10
South Korea's Ministry of Food and Drug Safety (MFDS) has proposed a significant amendment, MFDS Notification 2026-508, to its In-Vitro Diagnostic (IVD) approval process. Announced on October 28, 2026, the proposal would allow manufacturers to use clinical performance data from the World Health Organization's (WHO) Prequalification program to satisfy local requirements. This episode details this new reliance pathway, its impact on IVD manufacturers seeking faster market access, and the critical public comment deadline of November 16, 2026. We explore the practical steps regulatory teams should take to prepare for this change and leverage it for a more efficient entry into the South Korean market. Key Questions: - What is South Korea's MFDS proposing for IVD approvals under Notification 2026-508? - How can the WHO Prequalification program accelerate market access in South Korea? - What specific data will be accepted through this new reliance pathway? - What is the deadline for submitting public comments on this proposal? - Which IVD manufacturers will benefit the most from this regulatory change? - How does this proposal align South Korea with global regulatory harmonization efforts? - What are the immediate actions regulatory teams should consider in response? - What happens if a manufacturer does not have WHO Prequalification? - What are the potential cost and time savings for IVD registrations? Sources: - https://www.meridiantrace.com/en/medical-device-regulatory-change-tracker How Pure Global can help: Pure Global offers end-to-end regulatory consulting to help MedTech and IVD companies achieve faster global market access. Our experts develop efficient regulatory strategies, manage technical dossier submissions, and act as your local representative in over 30 countries, including South Korea. We leverage advanced AI to streamline document compilation and track regulatory changes, ensuring your products remain compliant. Whether you are a startup or a multinational enterprise, Pure Global can help you navigate complex pathways like the new MFDS proposal for IVDs. Visit us at https://pureglobal.com, contact us at [email protected], or explore our free AI tools and device database at https://pureglobal.ai.
UK MHRA Annual Fee Deadline: Urgent Action Required by November 6, 2026
2026/11/09
The UK MHRA has recalculated the 2026/2027 annual registration fees for medical devices, including those previously marked as 'put into service only.' This urgent update, announced on October 16, 2026, sets a hard payment deadline of November 6, 2026. Failure to pay the revised fee by this date will result in the suspension of the manufacturer's or UK Responsible Person's DORS account, immediately halting market access in Great Britain. This episode details the reasons for the recalculation, who is affected, and the critical steps your team must take now to avoid business disruption. Key Questions: - What prompted the UK MHRA to recalculate the 2026/2027 annual fees? - What is the firm deadline for paying the revised annual fee? - What happens if a manufacturer or UKRP fails to pay the fee by the deadline? - Which specific device types were added to the new fee calculation? - How can you check your new invoice in the DORS system? - What immediate steps should regulatory teams take to avoid market access disruption in Great Britain? - Who is ultimately responsible for paying the fee: the manufacturer or the UK Responsible Person? - How can you ensure your device portfolio in DORS is accurate? - Why is this deadline considered non-negotiable by the MHRA? Sources: - https://www.pure-global.com/news/uk-mhra-2026-27-annual-fee-recalculation-6-nov-deadline How Pure Global can help: Pure Global provides comprehensive regulatory consulting and acts as a UK Responsible Person (UKRP) for MedTech and IVD companies, ensuring seamless market access to Great Britain. Our local experts and advanced AI tools streamline the entire lifecycle, from regulatory strategy and technical dossier submission to post-market surveillance and continuous regulatory monitoring. We help you navigate complex requirements like the MHRA's DORS system and urgent fee updates, ensuring your compliance is maintained without disruption. To learn how we can accelerate your global market access, visit us at https://pureglobal.com, contact us at [email protected], or explore our free AI tools and device database at https://pureglobal.ai.
China NMPA GMP 2026: Navigating Post-Implementation Compliance and Inspections
2026/11/08
As of November 1, 2026, China's revised Good Manufacturing Practice (GMP) for medical devices is in full effect, replacing the 2014 version. This episode explains the immediate consequences for manufacturers, as the transition period is now over. We break down the stricter quality management system requirements from NMPA Announcement No. 107 of 2025 and discuss what NMPA inspectors will now be looking for during audits, based on the simultaneously effective 'Guidelines for Inspection of Good Manufacturing Practice.' Learn the practical steps your regulatory and quality teams must take now to ensure continued market access and avoid non-compliance penalties. Key Questions: - What are the most significant changes in China's new GMP versus the previous 2014 version? - How does the new regulation impact design controls, supplier management, and risk management? - With the transition period over, what are the immediate risks for non-compliant manufacturers? - What specific evidence will NMPA inspectors look for under the new inspection guidelines? - Are there different requirements for domestic versus foreign manufacturers? - What are the penalties for failing a GMP inspection under the new rules? - What practical steps can be taken right now to verify and ensure full compliance? Sources: - https://www.emergobyul.com/news/china-nmpa-quality-management-system-qms-legislation-take-effect-november-1-2026 - https://www.dqs-med.com/en/news/chinas-new-medical-device-gmp-in-force-from-1-nov-2026 - https://cisema.com/en/cisema-news/china-nmpa-issues-new-medical-device-gmp-inspection-guidelines/ - https://www.easymedicaldevice.com/news/medical-device-regulatory-update-november-2026/ - https://english.nmpa.gov.cn/2026-11/04/c_930869.htm How Pure Global can help: Pure Global provides end-to-end regulatory solutions to help MedTech companies navigate complex markets like China. Our local experts can conduct a comprehensive gap analysis of your QMS against the new NMPA GMP and inspection guidelines, develop a remediation plan, and assist in updating your technical documentation. With in-country representation, we act as your local contact for NMPA communications and inspection support, ensuring you maintain compliance and market presence. Our AI-powered tools streamline dossier preparation and regulatory intelligence, accelerating your path to market. Contact us at [email protected] or visit https://pureglobal.com. Explore our free AI tools and global device database at https://pureglobal.ai.
Australia TGA CDSS Exemption Changes: New 2026 Rules for SaMD
2026/11/07
Australia's Therapeutic Goods Administration (TGA) has significantly narrowed the exemption criteria for Clinical Decision Support Software (CDSS), with new rules taking effect on November 1, 2026. This episode details the two key changes: exempt CDSS must not be intended to make a diagnosis on its own, and it must transparently display the logic and sources behind its recommendations for a healthcare professional to verify. We discuss how this impacts Software as a Medical Device (SaMD) manufacturers whose products may no longer qualify for exemption and will now require full TGA registration. Learn the practical steps your team must take now to assess your product, perform a gap analysis, and prepare a regulatory strategy to ensure continued market access in Australia. Key Questions: - What are the specific changes to Australia's CDSS exemption rules for 2026? - When do the new TGA requirements for SaMD take effect? - How does the TGA now define a CDSS that is exempt from regulation? - What does it mean for software to 'display its logic' for a healthcare professional? - Will my previously exempt diagnostic software now require TGA registration? - What are the first steps to take if my CDSS no longer qualifies for exemption? - How should I re-evaluate my product's claims and intended purpose? - What is the impact of these changes on AI-enabled medical software startups in Australia? Sources: - https://www.viridianlawyers.com.au/blog/saas-lawyer-australia/software-as-a-medical-device-how-the-tga-regulates-digital-health-and-ai-enabled-medical-software-startups-in-australia - https://www.medtech.org.au/september-28th-october-2nd-2026/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies navigate complex global markets like Australia. Our experts can assist with re-evaluating your CDSS against the new TGA criteria, developing a comprehensive regulatory strategy if registration is now required, and acting as your official Australian Sponsor. We use advanced AI tools to efficiently compile, manage, and submit the technical dossier needed for TGA approval, streamlining your path to compliance. Whether you are a startup or a multinational, we ensure you can maintain and expand your market presence efficiently. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and regulatory database at https://pureglobal.ai.
India Medical Device Import Rules 2026: Proposed Expansion of Gateways
2026/11/06
On November 3, 2026, India's Ministry of Health proposed a draft amendment to expand the list of authorized import gateways for medical devices, drugs, and cosmetics under Rule 43A of the Drugs Rules, 1945. This episode details the twelve new proposed locations, including ten Inland Container Depots (ICDs) and the new Noida International Airport. We explore the government's goal of reducing logistics costs and transit times, analyze the impact on supply chain strategies for manufacturers, and outline practical steps that regulatory and logistics teams should take now to prepare for this significant change. Key Questions: - What specific changes are proposed to India's Rule 43A for medical device imports? - Which ten new Inland Container Depots are being considered as import gateways? - How will the inclusion of Noida International Airport affect supply chains in North India? - What is the government's primary goal with this proposed expansion? - How can this change reduce logistics costs and transit times for medical device importers? - What does this mean for manufacturers currently using congested ports like Mumbai or Chennai? - Is this a final rule, or is there an opportunity for industry feedback? - What practical steps should regulatory and supply chain teams take in response to this proposal? Sources: - https://www.thehindu.com/sci-tech/health/centre-proposes-10-new-import-gateways-for-drugs-medical-devices/article68828485.ece - https://maritimegateway.com/india-proposes-wider-import-gateway-network-for-medicines-and-medical-devices/ - https://www.business-standard.com/policy/centre-proposes-expanding-import-gateways-for-drugs-medical-devices-126110300424_1.html How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping them access global markets faster. Our experts develop efficient regulatory strategies, manage technical dossier submissions using advanced AI, and act as your local representative in over 30 markets, including India. We help you navigate complex requirements, from initial market research to post-market surveillance, ensuring your products remain compliant. To learn how Pure Global can streamline your market access, visit us at https://pureglobal.com, contact us at [email protected], or explore our free regulatory AI tools and database at https://pureglobal.ai.
Tanzania TMDA Medical Device Registration Fees 2027: Key Deadlines
2026/11/05
The Tanzania Medicines and Medical Devices Authority (TMDA) has announced its annual retention fee schedule for 2027, introducing critical deadlines that medical device manufacturers must meet to maintain market access. This episode details the multi-stage process, starting with the mandatory continued-marketing declaration due by November 1, 2026. We break down the fee structure—USD 200 per registered device and USD 50 per notified device—and the final payment deadline of January 31, 2027. We also explain the severe consequences of non-compliance, including registration suspension and import permit blocks, which take effect from April 1, 2027. Tune in for practical steps your team can take now to prepare for these requirements and avoid costly disruptions to your business in Tanzania. Key Questions: - What are the key deadlines for Tanzania's 2027 medical device retention fees? - How much are the annual fees for registered and notified medical devices in Tanzania? - What is the continued-marketing declaration and why is the November 1, 2026 deadline so important? - What happens if manufacturers miss the TMDA's payment deadline of January 31, 2027? - Why is the April 1, 2027 date critical for maintaining market access in Tanzania? - What immediate steps should regulatory teams take to prepare for these requirements? - How can companies avoid registration suspension and import permit blocks for their devices? - What are the financial and logistical implications of TMDA's 2027 fee schedule for manufacturers? - How should companies coordinate with their local Tanzanian representatives for this process? Sources: - https://pureglobal.com/news/medical-device-regulatory-news-and-updates/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech companies access and maintain their presence in over 30 global markets, including Tanzania. Our local experts can act as your in-country representative, manage submission of declarations, and ensure timely fee payments to authorities like the TMDA. We leverage advanced AI and data tools to develop efficient regulatory strategies, compile technical dossiers, and monitor changes that impact your registrations. Whether you need to manage annual renewals or expand into new markets, Pure Global streamlines the process. Visit us at https://pureglobal.com, contact us at [email protected], or explore our free regulatory AI tools and device database at https://pureglobal.ai.
Brazil ANVISA Recognized Technical Standards: New Lists for Orthopedic and Health-Use Materials
2026/11/04
On October 22, 2026, Brazil's ANVISA released three workbooks of recognized technical standards impacting medical device manufacturers. This episode details the contents of the new "Transversal Standards" (v1.0) and "Health-Use Materials" (v0.0) lists, as well as the updated "Orthopedic Implantable Materials" (v1.1) list. We explain how voluntary compliance with these standards can create a presumption of conformity, potentially streamlining the review of technical dossiers. We cover which device categories are affected and provide practical steps for regulatory teams to perform a gap analysis and update their submission strategies for the Brazilian market. Key Questions: - What are the three new technical standard lists ANVISA published on October 22, 2026? - How do these recognized standards impact the review process for medical device submissions in Brazil? - Which specific device types are affected by the new lists for orthopedic and health-use materials? - What is the significance of the new "transversal standards" list for all device manufacturers? - Is compliance with these ANVISA-recognized standards mandatory? - How can referencing these standards streamline your technical dossier preparation? - What practical steps should your regulatory team take in response to these updates? - Why is it important to monitor these ANVISA workbooks for future versions? Sources: - https://www.pure-global.com/insights/anvisa-publishes-three-recognized-device-standards-lists How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech companies access global markets faster. Our experts can help you navigate complex regulatory changes, such as ANVISA's new recognized technical standards, by developing a clear market access strategy, performing gap analyses, and compiling robust technical dossiers that meet local requirements. With a presence in over 30 countries, we act as your local representative and ensure ongoing compliance. Visit us at https://pureglobal.com or contact us at [email protected]. Explore our free AI regulatory tools and global device database at https://pureglobal.ai to streamline your research and submissions.
South Korea MFDS Proposes 'One-Stop' Certification for Class II Medical Devices
2026/11/03
South Korea's Ministry of Food and Drug Safety (MFDS) has proposed a significant amendment to streamline the certification process for Class II medical devices. This episode details the new 'one-stop' pathway, which combines the technical document review and certification application into a single, simultaneous submission to the National Institute of Medical Device Safety Information (NIDS). We explore how this change is expected to reduce the total processing time from approximately 40 days to 25 days and offer practical advice for manufacturers to prepare for this accelerated market access route following the closure of the public comment period on October 26, 2026. Key Questions: - What is South Korea's MFDS proposing for Class II medical device certification? - How does the new 'one-stop' process differ from the current sequential system? - What is the expected reduction in review time for Class II devices? - What is the role of the National Institute of Medical Device Safety Information (NIDS) in the new process? - When did the public comment period for this proposed amendment close? - How can manufacturers prepare their technical documentation for this potential change? - Why is a complete and accurate initial submission more critical under a simultaneous review process? - What practical steps should regulatory teams take to leverage this accelerated pathway? - How could this change impact market entry timelines and commercial strategy? Sources: - https://www.gca-korea.com/post/korean-mfds-to-introduce-a-one-stop-certification-and-review-process-for-class-ii-medical-devices - https://www.youtube.com/watch?v=example_placeholder_for_25 How Pure Global can help: Pure Global streamlines global market access for MedTech and IVD companies. For South Korea, we act as your local representative, manage interactions with the MFDS and NIDS, and prepare your technical dossier for submission. Our experts can help you navigate the proposed 'one-stop' certification process for Class II devices, ensuring your submission is complete and accurate to maximize the benefits of the accelerated timeline. We combine local expertise with advanced AI to get your products to market faster. Visit https://pureglobal.com, email us at [email protected], or explore our free AI tools and device database at https://pureglobal.ai.
FDA IDE Electronic Submission Guidance: Preparing for the New Template
2026/11/02
This episode covers the US FDA's new draft guidance, released on October 27, 2026, which introduces a standardized 'Electronic Submission Template for Investigational Device Exemption (IDE) Applications.' We discuss the FDA's goals of improving submission consistency and review efficiency, the key components of the proposed template, and who will be most affected. We also highlight the critical December 28, 2026, deadline for industry feedback and provide practical steps for regulatory and clinical teams to prepare for this upcoming change. Key Questions: - What is the new FDA draft guidance on IDE electronic submissions? - Why is the FDA introducing a standardized template for IDE applications? - Who will be most affected by this proposed change? - What is the critical deadline for providing feedback to the FDA on this draft guidance? - How does the new template aim to improve the IDE review process? - What are the key sections of the proposed electronic submission template? - What practical steps should regulatory teams take in response to this draft guidance? - How can sponsors prepare their internal processes for this new format? Sources: - https://www.federalregister.gov/documents/2026/10/28/2026-23501/electronic-submission-template-for-investigational-device-exemption-ide-applications-draft - https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-submission-template-investigational-device-exemption-ide-applications - https://www.fda.gov/medical-devices/news-events-medical-devices/cdrh-new-news-and-updates How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech companies access global markets faster. Our experts can help you navigate the new FDA IDE submission requirements, develop an efficient regulatory strategy for your US clinical trials, and compile your technical dossier using advanced AI tools. We act as your local representative and ensure your submissions are complete and compliant to minimize delays. For support with your market access strategy, visit us at https://pureglobal.com or contact us at [email protected]. Explore our free AI regulatory tools and device database at https://pureglobal.ai.

Podcast reviews

Read Medical Device Global Market Access podcast reviews


5 out of 5
1 reviews

Podcast sponsorship advertising

Start advertising on Medical Device Global Market Access relevant audience podcasts


What do you want to promote?